This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition has the capacity to treating or preventing a virus infection in a subject. ##STR00001##

Disclosed herein a method for converting (cannabidiol) CBD into a composition comprising Δ.sup.8-tetrahydrocannabinol (Δ.sup.8-THC) and Δ.sup.9-tetrahydrocannabinol (Δ.sup.9-THC), in which the composition has a Δ.sup.8-THC:Δ.sup.9-THC ratio that is greater than 1.0:1.0. The method comprises contacting the CBD with a Lewis-acidic heterogeneous reagent under protic, aprotic, or neat reaction conditions comprising: (i) a reaction temperature that is greater than a threshold reaction temperature for the Lewis-acidic heterogeneous reagent and the solvent system; and (ii) a reaction time that is greater than a threshold reaction time for the Lewis-acidic heterogeneous reagent, the solvent system, and the reaction temperature.

The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from the cannabinoid sulfonate esters.

The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from the cannabinoid sulfonate esters.

A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include Δ.sup.9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including Δ.sup.9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable Δ8-tetrahydrocannabinol. The known and novel analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis or cannabis oil.

A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include Δ.sup.9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including Δ.sup.9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable Δ8-tetrahydrocannabinol. The known and novel analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis or cannabis oil.

A chromene compound which can exhibit excellent photochromic properties. The chromene compound is represented by the following formula (1). In the formula, at least one of R.sup.1 or R.sup.2 represents the group having the radical-polymerizable group, wherein the group having a radical-polymerizable group is represented by the following formula (2) (wherein R.sup.10 represents a linear or branched alkylene group having 1 to 10 carbon atoms and l represents an integer of from 0 to 50); and the ring Z that is represented by the following formula (Z) and is spiro-bonded to a carbon atom located at position-13 in the formula (1) is preferably an aliphatic cyclic group that may have a substituent, the group having 3 to 20 carbon atoms for forming the ring together with the carbon atom at the 13-position, or the like.

##STR00001##

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

A family of α-glucosidase inhibitors are identified. Exemplary α-glucosidase inhibitors may be obtained from Heterophragma adenophyllum seem. The inhibitors are used to lower blood sugar levels and thus to treat diseases related to or characterized by high blood sugar, such as diabetes.

A method of modifying a naturally occurring Cannabis raw plant material, a purified Cannabis product from a naturally occurring Cannabis raw plant material, and a modified Cannabis product from a naturally occurring Cannabis raw plant material. The method includes selectively extracting at least some volatile organic compounds from a naturally occurring Cannabis raw plant material. At least some of a naturally occurring potential cannabinoid content in the Cannabis raw plant material is retained after removal of the at least some of the volatile organic compounds as well as substantially all of the physical structure of the Cannabis raw plant material.